Advances in cytoreductive surgery of gynecologic cancers

1998 ◽  
pp. 203-217 ◽  
Author(s):  
Ivor Benjamin ◽  
Stephen C. Rubin
Keyword(s):  
Cytoreductive Surgery ◽  
Gynecologic Cancers

scholarly journals Enhanced recovery after surgery protocols improve time to return to intended oncology treatment following interval cytoreductive surgery for advanced gynecologic cancers

2021 ◽  
pp. ijgc-2021-002495
Author(s):  
Joan Isabelle Tankou ◽  
Olivia Foley ◽  
Michele Falzone ◽  
Rajeshwari Kalyanaraman ◽  
Kevin M Elias
Keyword(s):  
Adjuvant Chemotherapy ◽  
Cytoreductive Surgery ◽  
Enhanced Recovery ◽  
Enhanced Recovery After Surgery ◽  
Gynecologic Oncology ◽  
Multivariate Logistic Regression Analysis ◽  
Gynecologic Cancers ◽  
Oncology Treatment ◽  
American Society ◽  
Eras Protocol

ObjectiveThe objective of this study was to determine whether the implementation of an enhanced recovery after surgery (ERAS) protocol is associated with earlier return to intended oncology treatment following interval cytoreductive surgery for advanced gynecologic cancers.MethodsParticipants comprised consecutive patients (n=278) with a preoperative diagnosis of stage IIIC or IV ovarian cancer, divided into those that received treatment before versus after implementation of an ERAS protocol at our institution. All patients received at least three cycles of neoadjuvant chemotherapy with a platinum based regimen and underwent interval cytoreduction via laparotomy with the intent to deliver additional cycles of chemotherapy postoperatively. The primary outcome was defined as the timely return to intended oncologic treatment, defined as the percentage of patients initiating adjuvant chemotherapy within 28 days postoperatively.ResultsThe study cohorts included 150 pre-ERAS patients and 128 post-ERAS patients. Median age was 65 years (range 58–71). Most patients (211; 75.9%) had an American Society of Anesthesiologists score of 3, and the median operative time was 174 min (range 137–219). Median length of stay was 4 days (range 3–5 days) in the pre-ERAS cohort versus 3 days (range 3–4) in the post-ERAS cohort (p<0.0001). At 28 days after operation, 80% of patients had resumed chemotherapy in the post-ERAS cohort compared with 64% in the pre-ERAS cohort (odds ratio (OR) 2.29, 95% confidence interval (CI) 1.36 to 3.84; p=0.002). In multivariate logistic regression analysis, the ERAS protocol was the strongest predictor of timely return to intended oncology treatment (OR 10.18, 95% CI 5.35 to 20.32).ConclusionAn ERAS protocol for gynecologic oncology patients undergoing interval cytoreductive surgery is associated with earlier resumption of adjuvant chemotherapy.

Other gynecologic cancers

2003 ◽  
Author(s):  
Eliane Duarte-Franco ◽  
Eduardo L. Franco
Keyword(s):  
Gynecologic Cancers

Predictive value of PET-CT imaging versus AGO-scoring in patients planned for cytoreductive surgery in recurrent ovarian cancer

2008 ◽  
Vol 68 (S 01) ◽  
Author(s):  
MS Lenhard ◽  
A Kirschenhofer ◽  
T Johnson ◽  
C Bruns ◽  
K Friese ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cytoreductive Surgery ◽  
Predictive Value ◽  
Recurrent Ovarian Cancer ◽  
Ct Imaging ◽  
Pet Ct

Non-gynecologic cancers in pregnant women

2018 ◽  
Vol 16 (2) ◽  
pp. 126-136
Author(s):  
Aleksandra Stupak ◽  
◽  
Anna Kwaśniewska ◽  
Keyword(s):  
Pregnant Women ◽  
Gynecologic Cancers
Sign in / Sign up

Export Citation Format

Share Document